Abstract
Treatment options for primary cutaneous aspergillosis in neonates are limited by the lack of pharmacokinetic and safety data of newer antifungal agents that are effective against Aspergillus spp. We report the successful treatment of cutaneous aspergillosis in an extremely low-birth-weight preterm infant with liposomal amphotericin B, voriconazole and micafungin, and provide pharmacokinetic profiles for voriconazole and micafungin.
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
MeSH terms
-
Amphotericin B / therapeutic use
-
Antifungal Agents / therapeutic use*
-
Aspergillosis / drug therapy*
-
Aspergillosis / microbiology
-
Dermatomycoses / drug therapy*
-
Dermatomycoses / microbiology
-
Echinocandins
-
Humans
-
Infant, Extremely Low Birth Weight
-
Infant, Newborn
-
Infant, Premature
-
Infant, Premature, Diseases / drug therapy*
-
Infant, Premature, Diseases / microbiology
-
Lipopeptides
-
Lipoproteins / therapeutic use
-
Micafungin
-
Peptides, Cyclic / therapeutic use
-
Pyrimidines / therapeutic use
-
Treatment Outcome
-
Triazoles / therapeutic use
-
Voriconazole
Substances
-
Antifungal Agents
-
Echinocandins
-
Lipopeptides
-
Lipoproteins
-
Peptides, Cyclic
-
Pyrimidines
-
Triazoles
-
liposomal amphotericin B
-
Amphotericin B
-
Voriconazole
-
Micafungin